Replimune Group, Inc. (REPL)
14.69
-0.08
(-0.54%)
USD |
NASDAQ |
Aug 24, 16:00
14.69
0.00 (0.00%)
After-Hours: 20:00
Replimune Group Enterprise Value : 1.157B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 1.157B |
| August 20, 2026 | 1.097B |
| August 19, 2026 | 1.160B |
| August 18, 2026 | 1.225B |
| August 17, 2026 | 1.145B |
| August 14, 2026 | 1.174B |
| August 13, 2026 | 1.192B |
| August 12, 2026 | 1.196B |
| August 11, 2026 | 1.063B |
| August 10, 2026 | 1.065B |
| August 07, 2026 | 929.44M |
| August 06, 2026 | 996.62M |
| August 05, 2026 | 910.12M |
| August 04, 2026 | 917.68M |
| August 03, 2026 | 916.84M |
| July 31, 2026 | 857.22M |
| July 30, 2026 | 370.98M |
| July 29, 2026 | 370.98M |
| July 28, 2026 | 365.94M |
| July 27, 2026 | 641.39M |
| July 24, 2026 | 731.25M |
| July 23, 2026 | 795.07M |
| July 22, 2026 | 819.43M |
| July 21, 2026 | 840.42M |
| July 20, 2026 | 799.27M |
| Date | Value |
|---|---|
| July 17, 2026 | 775.76M |
| July 16, 2026 | 716.13M |
| July 15, 2026 | 729.57M |
| July 14, 2026 | 745.52M |
| July 13, 2026 | 750.98M |
| July 10, 2026 | 839.58M |
| July 09, 2026 | 849.66M |
| July 08, 2026 | 850.50M |
| July 07, 2026 | 883.25M |
| July 06, 2026 | 879.89M |
| July 02, 2026 | 889.13M |
| July 01, 2026 | 858.90M |
| June 30, 2026 | 846.30M |
| June 29, 2026 | 769.13M |
| June 26, 2026 | 804.69M |
| June 25, 2026 | 763.34M |
| June 24, 2026 | 774.92M |
| June 23, 2026 | 787.32M |
| June 22, 2026 | 767.47M |
| June 18, 2026 | 685.58M |
| June 17, 2026 | 669.87M |
| June 16, 2026 | 568.95M |
| June 15, 2026 | 583.84M |
| June 12, 2026 | 577.22M |
| June 11, 2026 | 555.72M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Moderna, Inc. | 54.06B |
| Kalaris Therapeutics, Inc. | 6.653M |
| Arrowhead Pharmaceuticals, Inc. | 12.07B |
| Oncolytics Biotech, Inc. | 101.41M |
| Sangamo Therapeutics, Inc. | 50.70M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -69.77M |
| Total Expenses (Quarterly) | 69.77M |
| EPS Diluted (Quarterly) | -0.7202 |
| Earnings Yield | -22.32% |
| Normalized Earnings Yield | -22.32 |